ICON PLC (ICLR)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2026-11-30 | Phase2 Readout | — |
Active Clinical Trials (17)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06252753 | Observational Study Protocol: LIVER-R | OTHER | Recruiting | 4,490 |
| NCT05127915 | US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism | OTHER | Active Not Recruiting | 854 |
| NCT04029363 | Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe ... | OTHER | Recruiting | 120 |
| NCT06941025 | Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women... | OTHER | Recruiting | 10 |
| NCT05721001 | French Registry Conducted on E-vita OPEN NEO | OTHER | Active Not Recruiting | 130 |
| NCT06385509 | A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months | PHASE4 | Active Not Recruiting | 110 |
| NCT06716606 | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Ass... | PHASE3 | Recruiting | 514 |
| NCT07647328 | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer | PHASE3 | Recruiting | 150 |
| NCT07059000 | A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | PHASE3 | Recruiting | 40 |
| NCT04620239 | ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | PHASE3 | Recruiting | 100 |
| NCT05710692 | Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | PHASE3 | Recruiting | 16 |
| NCT06328608 | A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease | PHASE3 | Recruiting | 22 |
| NCT03513939 | A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation | PHASE2 | Active Not Recruiting | 17 |
| NCT05693909 | A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes | PHASE2 | Recruiting | 90 |
| NCT05997264 | Anthrax AV7909 Boost Evaluation Study | PHASE2 | Active Not Recruiting | 220 |
| NCT07199569 | Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells | PHASE2 | Active Not Recruiting | 970 |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | PHASE2 | Recruiting | 213 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.